View Item 

Show simple item record

Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial
dc.contributor.authorRamalho, Sergio H.R.
dc.contributor.authorClaggett, Brian L.
dc.contributor.authorSweitzer, Nancy K.
dc.contributor.authorFang, James C.
dc.contributor.authorShah, Sanjiv J.
dc.contributor.authorAnand, Inder S.
dc.contributor.authorPitt, Bertram
dc.contributor.authorLewis, Eldrin F.
dc.contributor.authorPfeffer, Marc A.
dc.contributor.authorSolomon, Scott D.
dc.contributor.authorShah, Amil M.
dc.date.accessioned2020-04-02T18:38:30Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-04-02T18:38:30Z
dc.date.issued2020-03
dc.identifier.citationRamalho, Sergio H.R.; Claggett, Brian L.; Sweitzer, Nancy K.; Fang, James C.; Shah, Sanjiv J.; Anand, Inder S.; Pitt, Bertram; Lewis, Eldrin F.; Pfeffer, Marc A.; Solomon, Scott D.; Shah, Amil M. (2020). "Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial." European Journal of Heart Failure 22(3): 557-559.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/154618
dc.publisherJohn Wiley & Sons, Ltd
dc.titleImpact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154618/1/ejhf1593_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154618/2/ejhf1593.pdf
dc.identifier.doi10.1002/ejhf.1593
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferenceAndrea R, Lopez‐Giraldo A, Falces C, Sobradillo P, Sanchis L, Gistau C, Heras M, Sabate M, Brugada J, Agusti A. Lung function abnormalities are highly frequent in patients with heart failure and preserved ejection fraction. Heart Lung Circ 2014; 23: 273 – 279.
dc.identifier.citedreferenceAgostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J 2005; 26: 159 – 164.
dc.identifier.citedreferenceHawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11: 130 – 139.
dc.identifier.citedreferenceAther S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998 – 1005.
dc.identifier.citedreferenceSchena M, Clini E, Errera D, Quadri A. Echo‐Doppler evaluation of left ventricular impairment in chronic cor pulmonale. Chest 1996; 109: 1446 – 1451.
dc.identifier.citedreferenceBarr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217 – 227.
dc.identifier.citedreferencePitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383 – 1392.
dc.identifier.citedreferencePfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34 – 42.
dc.identifier.citedreferenceShah AM, Shah SJ, Anand IS, Sweitzer NK, O’Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD; TOPCAT Investigators. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail 2014; 7: 104 – 115.
dc.identifier.citedreferenceKomajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, Demets D, Massie BM. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I‐PRESERVE). Circ Heart Fail 2011; 4: 27 – 35.
dc.identifier.citedreferenceOlson TP, Johnson BD, Borlaug BA. Impaired pulmonary diffusion in heart failure with preserved ejection fraction. JACC Heart Fail 2016; 4: 490 – 498.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1593_am.pdf
Size:
159.6KB
Format:
PDF
View/Open
Name:
ejhf1593.pdf
Size:
447.3KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.